ArticlebioRxiv : the preprint server for biology2025
Glycan Profiling Identifies Chondroitin-4-sulfate as a Biomarker for Platinum Response and Therapeutic Target in Ovarian Cancer.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
For women with advanced ovarian cancer (OC), remission is typically achieved through surgery and combination chemotherapy, with duration largely dependent on tumor sensitivity to platinum-based drugs. Here, we show that tumor-associated glycosaminoglycans (GAGs) influence platinum drug efficacy in preclinical models of ovarian cancer. Due to the complexity of GAG biosynthesis and the involvement of multiple enzymes, traditional transcriptomic and proteomic approaches cannot accurately estimate their levels or correlation with patient response and survival. To address this, we quantitatively analyzed the full compositional profile of GAGs in OC patient-derived xenograft (PDX) models with known carboplatin sensitivity. Our results revealed a significant correlation between carboplatin resistance and high levels of the predominant GAG sequence, chondroitin-4-sulfate (C4S). Further investigation in cellular models demonstrated that high GAG expression reduces carboplatin uptake, DNA adduct formation, and tumor accumulation, whereas the opposite effect was observed for Triplatin, a GAG-targeting platinum agent. These trends were further validated in vivo, where treatment of OC PDX models with varying C4S levels confirmed that carboplatin efficacy decreases while Triplatin activity increases in tumors with high C4S expression. Based on these findings, we established a C4S cut-off score to predict tumor sensitivity, identifying a threshold above which tumors are likely to be carboplatin-resistant but Triplatin-sensitive. Analysis of patient tissue microarrays estimated that 40-83% of OC tumors, depending on subtype, exhibit high C4S expression. Collectively, these findings highlight the predictive power of C4S as a biomarker for platinum response and support the clinical evaluation of Triplatin as a targeted treatment for patients with carboplatin-resistant tumors expressing high levels of C4S.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.